1. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative
- Author
-
Khean-Lee Goh, Atsushi Nakajima, Ajay Duseja, Khek Yu Ho, Yock Young Dan, Myeong Jun Song, Kento Imajo, Phunchai Charatcharoenwitthaya, George Boon-Bee Goh, Wah-Kheong Chan, Jian-Gao Fan, Sombat Treeprasertsuk, Panyavee Pitisuttithum, and Vincent Wai-Sun Wong
- Subjects
Liver Cirrhosis ,Male ,Biopsy ,Severity of Illness Index ,0302 clinical medicine ,Interquartile range ,Non-alcoholic Fatty Liver Disease ,Nonalcoholic fatty liver disease ,Aged, 80 and over ,education.field_of_study ,Gastroenterology ,Age Factors ,General Medicine ,gamma-Glutamyltransferase ,Middle Aged ,Gut and Obesity in Asia ,Observational Studies as Topic ,Liver ,Cardiovascular Diseases ,030220 oncology & carcinogenesis ,Population study ,030211 gastroenterology & hepatology ,Female ,QRISK ,Adult ,medicine.medical_specialty ,Asia ,Population ,Observational Study ,Risk Assessment ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,education ,Gamma glutamyl transferase ,Aged ,Retrospective Studies ,business.industry ,Retrospective cohort study ,medicine.disease ,Cardiovascular risk ,Obesity ,Cross-Sectional Studies ,Heart Disease Risk Factors ,Relative risk ,business ,Biomarkers - Abstract
BACKGROUND Gamma-glutamyl transferase (GGT) is associated with the risk of cardiovascular disease (CVD) in the general population. AIM To identify the association of baseline GGT level and QRISK2 score among patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD). METHODS This was a retrospective study involving 1535 biopsy-proven NAFLD patients from 10 Asian centers in 8 countries using data collected by the Gut and Obesity in Asia (referred to as "GO ASIA") workgroup. All patients with available baseline GGT levels and all 16 variables for the QRISK2 calculation (QRISK2-2017; developed by researchers at the United Kingdom National Health Service; https://qrisk.org/2017/; 10-year cardiovascular risk estimation) were included and compared to healthy controls with the same age, sex, and ethnicity. Relative risk was reported. QRISK2 score > 10% was defined as the high-CVD-risk group. Fibrosis stages 3 and 4 (F3 and F4) were considered advanced fibrosis. RESULTS A total of 1122 patients (73%) had complete data and were included in the final analysis; 314 (28%) had advanced fibrosis. The median age (interquartile range [IQR]) of the study population was 53 (44-60) years, 532 (47.4%) were females, and 492 (43.9%) were of Chinese ethnicity. The median 10-year CVD risk (IQR) was 5.9% (2.6-10.9), and the median relative risk of CVD over 10 years (IQR) was 1.65 (1.13-2.2) compared to healthy individuals with the same age, sex, and ethnicity. The high-CVD-risk group was significantly older than the low-risk group (median [IQR]: 63 [59-67] vs 49 [41-55] years; P < 0.001). Higher fibrosis stages in biopsy-proven NAFLD patients brought a significantly higher CVD risk (P < 0.001). Median GGT level was not different between the two groups (GGT [U/L]: Median [IQR], high risk 60 [37-113] vs low risk 66 [38-103], P = 0.56). There was no correlation between baseline GGT level and 10-year CVD risk based on the QRISK2 score (r = 0.02). CONCLUSION The CVD risk of NAFLD patients is higher than that of healthy individuals. Baseline GGT level cannot predict CVD risk in NAFLD patients. However, advanced fibrosis is a predictor of a high CVD risk.
- Published
- 2020